Table 3 Between-group comparisons and effect sizes on primary and secondary outcome measures at post-treatment and 3- and 12-month follow-up

NFA vs. WL

−57.78***

d = −1.13 (−1.81, −.46)

–

–

NFA + TG vs. WL

−66.45***

d = − 1.27 (− 1.98, −.56)

–

–

NFA vs. NFA + TG

8.67

d = .23 (−.46, .93)

−.25

d = .15 (−.77, 1.07)

36.90

NFA vs. WL

− 17.23***

d = − 1.51 (−.2.13, −.71)

–

–

NFA + TG vs. WL

−17.68***

d = − 1.21 (− 1.92, −.49)

–

–

NFA vs. NFA + TG

.46

d = .03 (−.66, .73)

−.53

d = .04 (−.86, .94)

9.11

Fear

NFA vs. WL

−.2.86***

d = − 1.40 (−2.10, −.69)

–

–

NFA + TG vs. WL

−3.06***

d = − 1.25 (− 1.96, −.54)

–

–

NFA vs. NFA + TG

.21

d = .08 (−.06, .78)

1.08

d = .34 (−.01, .68)

1.77*

NFA vs. WL

−3.83***

d = − 1.48 (− 2.19, −.76)

–

–

NFA + TG vs. WL

−3.83***

d = − 1.21 (− 1.91, −.51)

–

–

NFA vs. NFA + TG

.004

d = −.02 (−.71, .66)

.66

d = .35 (−.55, 1.25)

1.70

NFA vs. WL

−3.42***

d = − 1.79 (− 2.54, − 1.04)

–

–

NFA + TG vs. WL

−3.95***

d = − 1.80 (− 2.56, − 1.04)

–

–

NFA vs. NFA + TG

.53

d = .19 (−.49, .87)

1.08

d = .48 (−.43, 1.40)

2.90*

NFA vs. WL

−3.07***

d = − 2.25 (− 3.10, − 1.45)

–

–

NFA + TG vs. WL

−3.11***

d = − 1.69 (− 2.44, −.94)

–

–

NFA vs. NFA + TG

.04

d = −.01 (−.69, .68)

.42

d = .36 (−.54, 1.39)

1.173

NFA vs. WL

1.50***

d = 2.00 (1.23, 2.46)

–

–

NFA + TG vs. WL

1.53***

d = 1.71 (.96, 2.46)

–

–

NFA vs. NFA + TG

−.26

d = −.03 (−.71, .65)

− 1.64

d = −.51 (− 1.42, .40)

−.58